TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01362543

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioural therapy (stress management)
Description: Following a manual

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioural Therapy (cognitive restructuring)
Description: Following a manual
Study: NCT02158715

Intervention type: DEVICE
Intervention: Site of smartphone on chest compressor' arm
Study: NCT01597934

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group A (Zeffix, Sebivo, Hepsera)
Description: Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group B (Baraclude, Viread)
Description: Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
Study: NCT02699489

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic donor nephrectomy
Description: Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open donor nephrectomy
Description: Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
Study: NCT01314261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: 5 mg or 25 mg tablets
Study: NCT01105585

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL
Description: Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof Natural IQ (SN60WF) IOL
Description: AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
Study: NCT00915148

Intervention type: OTHER
Intervention: Ultrasound examination
Description: Trans-abdominal and trans-perineal 3D ultrasound examination
Study: NCT00882739

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel 300 mg
Description: Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg
Description: Patients will receive a 600 mg clopidogrel loading dose at first medical contact

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clopidogrel 900 mg
Description: Patients will receive a 900 mg clopidogrel loading dose at first medical contact
Study: NCT01314261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: 5 mg or 25 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-267
Description: 5 mg or 25 mg tablets
Study: NCT04190797

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation + patiente controled anaethesia (PCA)
Description: Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device connected, 24h and 48h after the peripheral nerve block (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
Study: NCT01500473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel
Description: Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
Study: NCT01106079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive management or Tight control
Description: Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard management - Control group
Description: The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
Study: NCT02032680

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based multi-family psychoeducational treatment
Description: This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-persons Multi-Family Group Psycho-Education treatment
Description: This intervention will provide the VA's evidence-based MFG. This intervention is delivered to Veterans and their families or other supporters using an in-person format.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual (TAU)
Description: Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
Study: NCT00435760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aclidinium bromide
Description: 200 micrograms, once daily, 1 day treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tiotropium
Description: 1 puff once daily, 1 day treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium
Description: 1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
Study: NCT04190797

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + patiente controled anaethesia (PCA)
Description: Patients in the immediate postoperateve of knee arthroplasty surgery treated with the Photobiomodulation device switched off, in 24h and 48h after peripheral nerve bloc (femoral nerve and obturator nerve). With conventional analgesia and with the device of PCA.
Study: NCT01976260

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fractional Radiofrequency

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1550-nm Fractional Photothermolysis
Study: NCT02983994

Intervention type: DEVICE
Intervention: TURBUHALER®

Intervention type: DEVICE
Intervention: SPIROMAX®
Study: NCT02391493

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional magnetic resonance imaging
Description: Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds).
Study: NCT04147936

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1665
Description: Dietary supplement: AXA1665

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: AXA1665
Description: Dietary supplement: AXA1665
Study: NCT03902535

Intervention type: OTHER
Intervention: Comprehensive Geriatric Assessment
Description: Complete comprehensive geriatric assessment

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment
Study: NCT04147936

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01467388

Intervention type: PROCEDURE
Intervention: selective laser trabeculoplasty (SLT)
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure

Intervention type: PROCEDURE
Intervention: selective laser trabeculoplasty (SLT)
Description: trabeculoplasty with an SLT-Laser to reduce intraocular pressure
Study: NCT03902535

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete quality of life assessment

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02659319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Lifestyle (FL)
Description: 12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Lifestyle (FL)
Description: 12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
Study: NCT05654155

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auricular acupressure
Description: Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: auricular acupressure
Description: Auricular acupressure therapy is a well-established treatment strategy whose foundations lie in Traditional Chinese Medicine and is a therapy that is increasingly used in Western medicine.
Study: NCT04919577

Intervention type: DIAGNOSTIC_TEST
Intervention: X-ray
Description: We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.

Intervention type: DIAGNOSTIC_TEST
Intervention: X-ray
Description: We defined RSS as (1) the presence of symptoms such as nausea, vomiting, or abdominal fullness, (2) refasting after liquid or semi-liquid diets, (3) imaging methods (X-ray, CT, upper gastroenterography) confirmed without mechanical obstruction. All three conditions must be met at the same time and should occur within 30 days after operation.
Study: NCT04477811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin K1
Description: vitamin k1 tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin k2
Description: vitamin k2 45 ug tablets twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo tablets
Study: NCT03753347

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2018-19 quadrivalent inactivated influenza vaccine
Description: A single age-appropriate dose of 2018-19 quadrivalent inactivated influenza vaccine
Study: NCT00369512

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
Study: NCT03403816

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Before School Physical Activity Program
Description: BOKS is a before school physical activity program offered at no cost to participating families that focuses on engaging elementary and middle school students in physical activity, skill development and brief nutrition education sessions that prepare them for a day of learning. The BOKS curriculum includes 12 weeks of instruction and 40 minutes of structured kid-friendly activities that include warm-ups, skill of the week, running, relay and obstacle course activities and nutritional tips. The BOKS team provides training for BOKS leaders free of charge each month. BOKS is currently being used in more than 1,800 schools in the US and Canada.
Study: NCT01314261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study: NCT00446407

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collaborative Stepped Care Intervention
Description: Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
Study: NCT01314261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study: NCT02659319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Lifestyle (FL)
Description: 12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
Study: NCT01314261

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pegylated interferon (pegIFN)
Description: Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
Study: NCT02659319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Lifestyle (FL)
Description: 12-week Family Food \& Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dynamics (FD)
Description: The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Dynamics (FD)
Description: The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group (PG)
Description: Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Group (PG)
Description: Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
Study: NCT02653716

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Orleans Intervention Method
Description: An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Case Management
Description: A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
Study: NCT02645617

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varnish
Description: Topical application to the teeth
Study: NCT03389737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Counseling on healthy behaviors with in person meetings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counseling
Description: Counseling on healthy behaviors with emails.
Study: NCT01314261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-267
Description: Participants received matching placebo tablet at each dose level for ABT-267.
Study: NCT02608099

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted apixaban
Description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Uninterrupted apixaban
Description: Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
Study: NCT01475981

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTK-853 or Placebo
Description: Tablets, single dose, fasted, fed or high-fat fed condition
Study: NCT00875940

Intervention type: OTHER
Intervention: Diagnostic imaging procedures.
Study: NCT02337725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TVP-1012
Description: TVP-1012 1mg Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT02917915

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Canadian Standardized PR
Description: Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional PR
Description: Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
Study: NCT04083755

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric Carboxymaltose Injection [Injectafer]
Description: 1000mg intravenous

Intervention type: OTHER
Group type: OTHER
Intervention: no treatment or oral iron supplementation
Description: No treatment or treatment oral with iron supplementation if iron-deficiency anemia